Ozempic Should NOT Be Used in Patients with Anorexia Nervosa or Bulimia Nervosa
Ozempic (semaglutide) is contraindicated and potentially dangerous for patients with anorexia nervosa and should be avoided in bulimia nervosa patients due to its mechanism of action that directly opposes treatment goals and could worsen eating disorder pathology.
Critical Mechanistic Concerns
Semaglutide's pharmacologic effects are fundamentally incompatible with eating disorder recovery:
Appetite suppression and reduced food intake: Semaglutide causes substantial reductions in ad libitum energy intake (24% reduction across meals), decreased hunger, reduced food cravings, and better "control of eating" 1. These effects directly contradict the therapeutic goals in anorexia nervosa, where patients need to increase food intake and normalize eating patterns.
Delayed gastric emptying: The medication causes significant delays in gastric emptying 2, which can exacerbate the early satiety and fullness complaints already present in eating disorder patients, making renourishment even more difficult.
Weight loss promotion: Semaglutide produces mean weight loss of 14.9% in non-diabetic patients 3, which is catastrophic for underweight anorexia nervosa patients who require weight restoration for medical stability and recovery.
Evidence-Based Treatment Standards
Current treatment guidelines emphasize:
Anorexia nervosa: Combination of renourishment and psychotherapy (CBT, supportive clinical management, IPT) with family-based therapy for adolescents 4. Psychotherapy is the treatment of choice, and there is no proof of efficacy for any pharmacotherapy regarding weight gain 5.
Bulimia nervosa: Antidepressants (particularly fluoxetine, the only FDA-approved medication) combined with eating disorder-focused CBT 4, 6. Psychotherapy remains first-line treatment 7.
Limited and Concerning Research on GLP-1 Agonists in Eating Disorders
The available evidence raises significant red flags:
A 2024 review explicitly warns that GLP-1 agonists "could exacerbate, or contribute to the development of, ED pathology and negatively impact ED treatment" 8. The authors conclude there is insufficient evidence to support the use of GLP-1s to treat ED symptoms.
While one retrospective study showed reduced Binge Eating Scale scores with semaglutide in binge eating disorder 9, this was an open-label study with significant design limitations and does not apply to anorexia or bulimia nervosa populations.
The mechanism that helps binge eating disorder (appetite suppression) is precisely what harms anorexia nervosa patients.
Clinical Pitfalls to Avoid
Do not prescribe semaglutide to:
- Any patient with current or past anorexia nervosa
- Patients with active bulimia nervosa, especially those who are underweight or at risk of medical complications
- Patients with subclinical eating disorder symptoms or body image disturbances who are seeking weight loss
Warning signs that semaglutide may be worsening eating pathology:
- Increasing preoccupation with weight/shape despite weight loss
- Development of restrictive eating patterns beyond medication effects
- Emergence of compensatory behaviors (purging, excessive exercise)
- Worsening body image despite physical changes
The Only Potential Exception: Binge Eating Disorder with Obesity
For patients with binge eating disorder (BED) who have obesity and no history of restrictive eating disorders, semaglutide might be considered as part of comprehensive treatment that includes psychotherapy 9. However:
- This remains off-label use
- Lisdexamfetamine is the only FDA-approved medication for BED 6
- Close monitoring for development of restrictive eating patterns is essential
- Psychotherapy (CBT) should remain the primary treatment
The fundamental principle: Semaglutide's appetite-suppressing, weight-reducing effects make it therapeutically incompatible with anorexia nervosa and potentially harmful in bulimia nervosa, where the treatment goal is normalized eating patterns, not further restriction or weight loss.